In advanced metastatic disease, second-generation immune checkpoint inhibitors (e.g., TIGIT, LAG3, TIM3) added to an ICI and anti-VEGF backbone suggests the future of first-line HCC treatment is moving towards triplet systemic therapy. Here, TIGIT is linked to metastatic neoplasm.